Back

Back to the future - digitalis therapy reloaded? The suitability for digitoxin treatment in a real-world, outpatient heart failure patient cohort

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: From classic drugs to new interventions in heart failure Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Miss Kata Czurko

Gottsegen National Cardiovascular Center, Budapest (Hungary)

5 More presentations in this session

Presentation thumbnail
Efficacy and safety of guideline-directed medical therapies according to background use of digoxin: Insights from RALES, PARADIGM-HF, and DAPA-HF
Doctor R. Helseth (Boston, US)
Abstract Slides Video
Presentation thumbnail
Six-month results from the ATHENS-HF FIH trial of the Adona Medical adjustable, biatrial pressure sensing interatrial shunt
Doctor K. Rommel (Mainz, DE)
Abstract Slides Video
Presentation thumbnail
Role of ferric carboxymaltose supplementation on comprehensive geriatric assessment in elderly patients with chronic heart failure
Doctor M. Scarcelli (Catanzaro, IT)
Abstract Slides Video
Presentation thumbnail
Contemporary characteristics and treatment patterns of patients with HFmrEF and HFpEF in Germany. A cross-sectional survey.
Doctor A. Michel (Basel, CH)
Abstract Slides Video
Presentation thumbnail
The positive effect of sacubitril/valsartan therapy on QRS width and QTC interval on electrocardiogram in heart failure patients with reduced ejection fraction
Doctor P. Kekovic (Prokuplje, RS)
Abstract Slides Video

Access the full session

Session thumbnail
From classic drugs to new interventions in heart failure

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of digitoxin in heart failure with reduced ejection fraction according to atrial fibrillation: Insights from DIGIT-HF
thumbnail
Congress Presentation
DIGIT­HF: Baseline characteristics compared to recent trials in heart failure with reduced ejection fraction
thumbnail
Congress Presentation
Efficacy and safety of guideline-directed medical therapies according to background use of digoxin: Insights from RALES, PARADIGM-HF, and DAPA-HF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources